Developer docs
API playgroundTry for free, no card

Search company profiles

Luminopia

Full company profile

uuid00008ol

Namestring
Luminopia
Legal namestring
Luminopia, Inc.
Websiteurl
luminopia.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Luminopia, Inc. is a privately held, Cambridge, Massachusetts-based digital therapeutics company founded in 2015-2016 that develops Luminopia One, an FDA-cleared VR-based digital therapeutic for amblyopia ("lazy eye") in children ages 4-12. The product works by streaming modified television content through a provided VR headset, applying dichoptic masking and contrast reduction to the stronger eye so that the brain learns to combine input from both eyes. Luminopia received FDA De Novo clearance in October 2021 for children ages 4-7 and expanded the indication in April 2025 to ages 8-12. Clinical evidence includes a Phase 3 pivotal trial of 117 patients showing significant vision improvement at 12 weeks (p=0.001), 85% median treatment completion, and 94% parental preference over patching.

Luminopia monetizes through a prescription-based, subscription digital therapeutic model. Pediatric ophthalmologists, optometrists, and orthoptists prescribe Luminopia One through EHR-integrated electronic prescribing, with fulfillment handled by partner pharmacy CoAssist Pharmacy (Orlando, FL) and additional distribution via a 2025 partnership with Pentec Health. The product is reimbursed by Anthem Blue Cross Blue Shield, CareFirst BlueCross BlueShield, and Highmark Health. The commercial motion is enterprise field sales, supported by a healthcare provider adherence portal (hcp.luminopia.com) that surfaces patient compliance data back to prescribers. A curated content library of 75 TV shows / 3,100+ episodes — licensed from DreamWorks, Nelvana, Sony/Crunchyroll, Pokémon, Sesame Workshop, Nickelodeon, PBS Kids, and NBCUniversal — drives the engagement layer and is a key commercial differentiator.

The company has raised approximately $21.7 million in cumulative funding across a 2022 $5.7M seed extension (led by ShangBay Capital, with Sony Innovation Fund, The Vertical Group, and SSI Strategy) and a 2023 $16M Series A (led by U.S. Venture Partners). It operates with 11-50 employees, a lean commercial organization, and a development pipeline aimed at extending the platform to additional neuro-visual disorders including strabismus and intermittent exotropia. Leadership includes co-founder and CEO Scott Xiao (MIT TR Innovators Under 35, Forbes 30 Under 30), co-founder and Chairman Dean Travers (Thiel Fellow), COO Hank Wu (formerly Biogen, Evelo Biosciences), CBO Brion Raymond (formerly Genentech, Clearside Biomedical), VP of Commercial Strategy Drew Mowery (formerly Genentech, bluebird bio, Ultragenyx), and VP of Engineering Sunny Atwal (formerly Moth+Flame, Littlstar). Strategic board members include Robert Langer (MIT, Moderna co-founder) and representatives from USVP and ShangBay Capital.

Short descriptiontext

Luminopia is a Cambridge, MA-based digital therapeutics company that developed Luminopia One, the only FDA-cleared VR-based digital therapeutic for amblyopia in children ages 4-12. It sells by prescription through pediatric eye care providers, with fulfillment via CoAssist Pharmacy and Pentec Health and coverage from major insurance payers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics, pediatric ophthalmology, amblyopia treatment, VR therapy, binocular therapy
Industry2 codes
PRIMARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAM
Vision Therapy & Orthoptics
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code2 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Ophthalmic Goods3851
Product category
Digital Therapeutics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Prescription Digital Therapeutic Subscription
TypeSubscription Recurring
Description

Luminopia generates revenue through a prescription-based digital therapeutic model. Healthcare providers prescribe the treatment, and patients receive the VR headset and ongoing therapy through pharmacy fulfillment. The treatment is covered by major insurance providers including Anthem Blue Cross Blue Shield, CareFirst BlueCross BlueShield, and Highmark Health, indicating a reimbursement-based revenue model.

luminopia.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain
Pricing details1 tier
1Prescription-based digital therapeutic for amblyopia
ModelSubscriptionBilling cadenceMonthly
Notes

Pricing details not publicly disclosed. Insurance coverage available through Anthem Blue Cross Blue Shield, CareFirst BlueCross BlueShield, and Highmark Health.

luminopia.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Luminopia develops and sells Luminopia One, an FDA-cleared digital therapeutic that uses a VR headset to stream modified TV content for binocular therapy in children ages 4-12 with amblyopia (lazy eye). The treatment is prescribed by pediatric ophthalmologists and optometrists, dispensed through CoAssist Pharmacy, and covered by major US insurance payers. The company also offers a healthcare provider Adherence Portal for monitoring patient compliance.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 85% median treatment completion rate in clinical trial
+4 more records
Product overview1 text field

Luminopia is a digital health company offering a single FDA-cleared product, Luminopia One, which uses VR headsets to stream TV content as therapy for amblyopia (lazy eye) in children ages 4-12. The product employs a dual-acting binocular mechanism involving contrast reduction and dichoptic masking to encourage both eyes to work together. Luminopia One is supplemented by a provider-facing Adherence Portal for monitoring patient compliance. The company's development pipeline explores applications for additional neuro-visual conditions including intermittent exotropia and strabismus. Content partnerships with entertainment companies (DreamWorks, Nelvana, Sony, Pokemon, Sesame Street, Nickelodeon, PBS, NBCUniversal, Crunchyroll) provide the TV content streamed through the VR system.

Product and service2 records
1Luminopia One
CategoryDigital Therapeutics
Description

FDA-cleared digital therapeutic using VR headsets to stream TV shows for amblyopia treatment in children ages 4-12. Uses a dual-acting binocular mechanism that reduces contrast to the stronger eye and applies dichoptic masking to encourage both eyes to work together. Treatment is one hour per day, six days per week, with significant vision improvement shown in as early as 4 weeks in a 12-week clinical trial.

2Luminopia Adherence Portal
CategoryHealthcare Provider Software
Description

Healthcare provider portal for monitoring patient treatment compliance, displaying weekly and overall adherence trends for each Luminopia One patient. Used by physicians and office staff to track treatment progress.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership13 partners
Strategic tierContent_PartnerTypeGTM or Marketing PartnerAnnounced on2025-10-28
Description

Collaboration with Crunchyroll (Sony Pictures Entertainment subsidiary) to incorporate anime content into Luminopia's platform for treating pediatric amblyopia using a digital therapeutic approach.

Strategic tierContent_PartnerTypeGTM or Marketing PartnerAnnounced on2025-10-01
Description

Content licensing agreement to integrate Pokémon content into Luminopia's FDA-cleared amblyopia therapy platform to boost patient engagement and treatment adherence among children.

Strategic tierDistribution_PartnerTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-03-01
Description

Partnership announced March 2025 to expand distribution of Luminopia's digital therapeutics for amblyopia and mild strabismus.

Strategic tierContent_PartnerTypeGTM or Marketing Partner
Description

Entertainment content partner providing Sesame Street content for Luminopia's curated content library used in vision therapy.

Strategic tierContent_PartnerTypeGTM or Marketing Partner
Description

Entertainment content partner providing content including How to Train Your Dragon and Puss in Boots for Luminopia's therapy platform.

Strategic tierContent_PartnerTypeGTM or Marketing Partner
Description

Entertainment content partner providing content for Luminopia's curated content library.

Strategic tierContent_PartnerTypeGTM or Marketing Partner
Description

Entertainment content partner providing content including SpongeBob SquarePants, Wild Kratts, and The Loud House for Luminopia's therapy platform.

Strategic tierContent_PartnerTypeGTM or Marketing Partner
Description

Entertainment content partner providing PBS Kids content for Luminopia's curated content library.

Strategic tierContent_PartnerTypeGTM or Marketing Partner
Description

Entertainment content partner providing content for Luminopia's curated content library.

10CoAssist Pharmacy
Strategic tierFulfillment_PartnerTypeChannel Partner/ Reseller/ Distributor
Description

Pharmacy fulfillment partner that receives electronic prescriptions from healthcare providers and handles shipment of VR headsets and therapy materials to patients.

luminopia.com
Strategic tierCoverage_PartnerTypeOthers
Description

Approved coverage for Luminopia's FDA-cleared digital therapeutic treatment for amblyopia in children aged 4 to 12.

Strategic tierCoverage_PartnerTypeOthers
Description

Insurance coverage approved for Luminopia's amblyopia treatment.

Strategic tierCoverage_PartnerTypeOthers
Description

Insurance coverage approved for Luminopia's pediatric amblyopia treatment.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Maker of EndeavorRx, the first FDA-cleared prescription digital therapeutic for pediatric ADHD. Closest direct comparable: prescription DTx business model targeting pediatric prescribers, reimbursed by payers, with software-led therapy delivered via consumer hardware.

TypeDirect peer
Description

Developed VR-based vision therapy software for amblyopia, strabismus, and other binocular vision disorders. Direct competitor in the VR digital therapy category for the same patient population Luminopia targets.

3Bynocs
TypeDirect peer
Description

Offers clinician-prescribed dichoptic digital therapy for amblyopia using web/browser-based delivery. Competes in the same binocular digital therapeutics category for amblyopia patients.

4AmblyoPlay
TypeDirect peer
Description

Software-based vision therapy for amblyopia and other binocular disorders delivered via home computers/tablets. Direct competitor in digital amblyopia therapy, though primarily consumer-direct rather than prescription-based.

5Pear Therapeutics
TypeDirect peer
Description

Pioneer in prescription digital therapeutics (reSET, reSET-O) that pursued FDA-cleared, payer-reimbursed software therapeutics for CNS indications. Closest historical peer for the prescription DTx commercial model, despite bankruptcy and asset divestiture in 2023.

TypeDirect peer
Description

Pediatric-focused digital health company with FDA-authorized autism diagnostic and therapeutic digital products. Comparable as a pediatric prescription DTx company pursuing payer reimbursement for childhood neuro-developmental conditions.

TypeDirect peer
Description

Prescription digital therapeutics company developing software-delivered therapies across multiple indications, with pharma partnerships (e.g., Otsuka). Comparable business model targeting FDA-cleared, payer-reimbursed digital therapeutics.

TypeDirect peer
Description

Digital therapeutics company whose Sleepio product is FDA-cleared and covered by major insurers for insomnia. Comparable prescription DTx commercial playbook: FDA pathway, payer coverage, employer/health system distribution.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with established pediatric ophthalmology presence; competes in the amblyopia treatment paradigm with atropine drops and has the resources to develop or acquire competing digital therapeutics.

TypeBroad incumbent
Description

Large pharmaceutical company that has invested heavily in digital therapeutics (e.g., partnership with Akili, Click Therapeutics). Represents both a potential strategic acquirer and an incumbent player with pediatric/commercial reach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Luminopia

Digital Therapeuticsluminopia.com

Luminopia is a Cambridge, MA-based digital therapeutics company that developed Luminopia One, the only FDA-cleared VR-based digital therapeutic for amblyopia in children ages 4-12. It sells by prescription through pediatric eye care providers, with fulfillment via CoAssist Pharmacy and Pentec Health and coverage from major insurance payers.

What Luminopia does

Luminopia, Inc. is a privately held, Cambridge, Massachusetts-based digital therapeutics company founded in 2015-2016 that develops Luminopia One, an FDA-cleared VR-based digital therapeutic for amblyopia ("lazy eye") in children ages 4-12. The product works by streaming modified television content through a provided VR headset, applying dichoptic masking and contrast reduction to the stronger eye so that the brain learns to combine input from both eyes. Luminopia received FDA De Novo clearance in October 2021 for children ages 4-7 and expanded the indication in April 2025 to ages 8-12. Clinical evidence includes a Phase 3 pivotal trial of 117 patients showing significant vision improvement at 12 weeks (p=0.001), 85% median treatment completion, and 94% parental preference over patching.

Luminopia monetizes through a prescription-based, subscription digital therapeutic model. Pediatric ophthalmologists, optometrists, and orthoptists prescribe Luminopia One through EHR-integrated electronic prescribing, with fulfillment handled by partner pharmacy CoAssist Pharmacy (Orlando, FL) and additional distribution via a 2025 partnership with Pentec Health. The product is reimbursed by Anthem Blue Cross Blue Shield, CareFirst BlueCross BlueShield, and Highmark Health. The commercial motion is enterprise field sales, supported by a healthcare provider adherence portal (hcp.luminopia.com) that surfaces patient compliance data back to prescribers. A curated content library of 75 TV shows / 3,100+ episodes — licensed from DreamWorks, Nelvana, Sony/Crunchyroll, Pokémon, Sesame Workshop, Nickelodeon, PBS Kids, and NBCUniversal — drives the engagement layer and is a key commercial differentiator.

The company has raised approximately $21.7 million in cumulative funding across a 2022 $5.7M seed extension (led by ShangBay Capital, with Sony Innovation Fund, The Vertical Group, and SSI Strategy) and a 2023 $16M Series A (led by U.S. Venture Partners). It operates with 11-50 employees, a lean commercial organization, and a development pipeline aimed at extending the platform to additional neuro-visual disorders including strabismus and intermittent exotropia. Leadership includes co-founder and CEO Scott Xiao (MIT TR Innovators Under 35, Forbes 30 Under 30), co-founder and Chairman Dean Travers (Thiel Fellow), COO Hank Wu (formerly Biogen, Evelo Biosciences), CBO Brion Raymond (formerly Genentech, Clearside Biomedical), VP of Commercial Strategy Drew Mowery (formerly Genentech, bluebird bio, Ultragenyx), and VP of Engineering Sunny Atwal (formerly Moth+Flame, Littlstar). Strategic board members include Robert Langer (MIT, Moderna co-founder) and representatives from USVP and ShangBay Capital.

Luminopia firmographics

Firmographics
Name
Luminopia
Legal name
Luminopia, Inc.
Website
https://luminopia.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Luminopia is a Cambridge, MA-based digital therapeutics company that developed Luminopia One, the only FDA-cleared VR-based digital therapeutic for amblyopia in children ages 4-12. It sells by prescription through pediatric eye care providers, with fulfillment via CoAssist Pharmacy and Pentec Health and coverage from major insurance payers.
Ownership category
akta.pro rank

Luminopia industry classification

Industry
Product category
Digital Therapeutics
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Ophthalmic Goods (3851)
akta.pro industry
PRIMARYHLAHAJAM
Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAM
Vision Therapy & Orthoptics

Keywords

  • Digital therapeutics
  • Pediatric ophthalmology
  • Amblyopia treatment
  • VR therapy
  • Binocular therapy

Where Luminopia is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Luminopia business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Supply Chain

Revenue model

  1. Prescription Digital Therapeutic Subscription: Luminopia generates revenue through a prescription-based digital therapeutic model. Healthcare providers prescribe the treatment, and patients receive the VR headset and ongoing therapy through pharmacy fulfillment. The treatment is covered by major insurance providers including Anthem Blue Cross Blue Shield, CareFirst BlueCross BlueShield, and Highmark Health, indicating a reimbursement-based revenue model.

Pricing tiers

ModelBillingPrice
SubscriptionMonthlyPrescription-based digital therapeutic for amblyopia

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Luminopia product offering

Product offering

Core offering

Luminopia develops and sells Luminopia One, an FDA-cleared digital therapeutic that uses a VR headset to stream modified TV content for binocular therapy in children ages 4-12 with amblyopia (lazy eye). The treatment is prescribed by pediatric ophthalmologists and optometrists, dispensed through CoAssist Pharmacy, and covered by major US insurance payers. The company also offers a healthcare provider Adherence Portal for monitoring patient compliance.

Product overview

Luminopia is a digital health company offering a single FDA-cleared product, Luminopia One, which uses VR headsets to stream TV content as therapy for amblyopia (lazy eye) in children ages 4-12. The product employs a dual-acting binocular mechanism involving contrast reduction and dichoptic masking to encourage both eyes to work together. Luminopia One is supplemented by a provider-facing Adherence Portal for monitoring patient compliance. The company's development pipeline explores applications for additional neuro-visual conditions including intermittent exotropia and strabismus. Content partnerships with entertainment companies (DreamWorks, Nelvana, Sony, Pokemon, Sesame Street, Nickelodeon, PBS, NBCUniversal, Crunchyroll) provide the TV content streamed through the VR system.

Differentiator

Problem solved

Functional benefit

Products and services

  • Luminopia One FDA-cleared digital therapeutic using VR headsets to stream TV shows for amblyopia treatment in children ages 4-12. Uses a dual-acting binocular mechanism that reduces contrast to the stronger eye and applies dichoptic masking to encourage both eyes to work together. Treatment is one hour per day, six days per week, with significant vision improvement shown in as early as 4 weeks in a 12-week clinical trial.
  • Luminopia Adherence Portal Healthcare provider portal for monitoring patient treatment compliance, displaying weekly and overall adherence trends for each Luminopia One patient. Used by physicians and office staff to track treatment progress.

Quantifiable outcome

  • 85% median treatment completion rate in clinical trial
  • +4 more outcomes

Companies that use Luminopia

Customer profile

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Luminopia technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Luminopia partnerships and signals

Strategic signal

Partnerships

13 partnerships are on record, tiered content_partner, distribution_partner, fulfillment_partner and coverage_partner.

  • Crunchyrollcontent_partnerGTM or Marketing Partner · 28 October 2025Collaboration with Crunchyroll (Sony Pictures Entertainment subsidiary) to incorporate anime content into Luminopia's platform for treating pediatric amblyopia using a digital therapeutic approach.
  • Pokémon Company Internationalcontent_partnerGTM or Marketing Partner · 1 October 2025Content licensing agreement to integrate Pokémon content into Luminopia's FDA-cleared amblyopia therapy platform to boost patient engagement and treatment adherence among children.
  • Pentec Health Inc.distribution_partnerChannel Partner/ Reseller/ Distributor · 1 March 2025Partnership announced March 2025 to expand distribution of Luminopia's digital therapeutics for amblyopia and mild strabismus.
  • Sesame Workshopcontent_partnerGTM or Marketing PartnerEntertainment content partner providing Sesame Street content for Luminopia's curated content library used in vision therapy.
  • Dreamworkscontent_partnerGTM or Marketing PartnerEntertainment content partner providing content including How to Train Your Dragon and Puss in Boots for Luminopia's therapy platform.
  • Nelvanacontent_partnerGTM or Marketing PartnerEntertainment content partner providing content for Luminopia's curated content library.
  • Nickelodeoncontent_partnerGTM or Marketing PartnerEntertainment content partner providing content including SpongeBob SquarePants, Wild Kratts, and The Loud House for Luminopia's therapy platform.
  • PBS Kidscontent_partnerGTM or Marketing PartnerEntertainment content partner providing PBS Kids content for Luminopia's curated content library.
  • NBCUniversalcontent_partnerGTM or Marketing PartnerEntertainment content partner providing content for Luminopia's curated content library.
  • CoAssist Pharmacyfulfillment_partnerChannel Partner/ Reseller/ DistributorPharmacy fulfillment partner that receives electronic prescriptions from healthcare providers and handles shipment of VR headsets and therapy materials to patients.
  • CareFirst BlueCross BlueShieldcoverage_partnerOthersApproved coverage for Luminopia's FDA-cleared digital therapeutic treatment for amblyopia in children aged 4 to 12.
  • Anthem Blue Cross Blue Shieldcoverage_partnerOthersInsurance coverage approved for Luminopia's amblyopia treatment.
  • Highmark Healthcoverage_partnerOthersInsurance coverage approved for Luminopia's pediatric amblyopia treatment.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Luminopia competitors and assessment

Company assessment

Direct peers

  • Akili Interactive: Maker of EndeavorRx, the first FDA-cleared prescription digital therapeutic for pediatric ADHD. Closest direct comparable: prescription DTx business model targeting pediatric prescribers, reimbursed by payers, with software-led therapy delivered via consumer hardware.
  • Vivid Vision: Developed VR-based vision therapy software for amblyopia, strabismus, and other binocular vision disorders. Direct competitor in the VR digital therapy category for the same patient population Luminopia targets.
  • Bynocs: Offers clinician-prescribed dichoptic digital therapy for amblyopia using web/browser-based delivery. Competes in the same binocular digital therapeutics category for amblyopia patients.
  • AmblyoPlay: Software-based vision therapy for amblyopia and other binocular disorders delivered via home computers/tablets. Direct competitor in digital amblyopia therapy, though primarily consumer-direct rather than prescription-based.
  • Pear Therapeutics: Pioneer in prescription digital therapeutics (reSET, reSET-O) that pursued FDA-cleared, payer-reimbursed software therapeutics for CNS indications. Closest historical peer for the prescription DTx commercial model, despite bankruptcy and asset divestiture in 2023.
  • Cognoa: Pediatric-focused digital health company with FDA-authorized autism diagnostic and therapeutic digital products. Comparable as a pediatric prescription DTx company pursuing payer reimbursement for childhood neuro-developmental conditions.
  • Click Therapeutics: Prescription digital therapeutics company developing software-delivered therapies across multiple indications, with pharma partnerships (e.g., Otsuka). Comparable business model targeting FDA-cleared, payer-reimbursed digital therapeutics.
  • Big Health: Digital therapeutics company whose Sleepio product is FDA-cleared and covered by major insurers for insomnia. Comparable prescription DTx commercial playbook: FDA pathway, payer coverage, employer/health system distribution.

Broad incumbents

  • Novartis: Global pharmaceutical incumbent with established pediatric ophthalmology presence; competes in the amblyopia treatment paradigm with atropine drops and has the resources to develop or acquire competing digital therapeutics.
  • Otsuka Pharmaceutical: Large pharmaceutical company that has invested heavily in digital therapeutics (e.g., partnership with Akili, Click Therapeutics). Represents both a potential strategic acquirer and an incumbent player with pediatric/commercial reach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

Luminopia social profiles

Digital presence

Luminopia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Luminopia leadership team

Management profile

Number of profiles

Profiles9 records

Luminopia funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Luminopia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luminopia

What does Luminopia do?

Luminopia develops and sells Luminopia One, an FDA-cleared digital therapeutic that uses a VR headset to stream modified TV content for binocular therapy in children ages 4-12 with amblyopia (lazy eye). The treatment is prescribed by pediatric ophthalmologists and optometrists, dispensed through CoAssist Pharmacy, and covered by major US insurance payers. The company also offers a healthcare provider Adherence Portal for monitoring patient compliance.

Is Luminopia a public or private company?

Luminopia is a private company. It is classified as venture growth investor backed and is currently operating.

When was Luminopia founded?

Luminopia was founded in 2016. It employs 11 to 50 people.

Where is Luminopia based?

Luminopia is headquartered in Cambridge, United States, in the North America region.

How does Luminopia make money?

One revenue line is on record: prescription Digital Therapeutic Subscription.

Who are Luminopia's main competitors?

Direct peers on record are Akili Interactive, Vivid Vision, Bynocs, AmblyoPlay, Pear Therapeutics, Cognoa, Click Therapeutics and Big Health. Broad incumbents are Novartis and Otsuka Pharmaceutical.

Does Luminopia have an API?

No public API is recorded for Luminopia.

What industry is Luminopia in?

Luminopia's product category is Digital Therapeutics. Its primary akta.pro industry code is HLAHAJAM, Pediatric Ophthalmology & Orthoptics Devices (Amblyopia Therapy, Strabismus Measurement & Treatment), with a secondary code of HLAKAKAM, Vision Therapy & Orthoptics. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Ophthalmology TimesData demonstrates efficacy of FDA-approved therapy for treating amblyopia in childrenLuminopia presented real-world data from its PUPiL Registry confirming the efficacy of its FDA-approved VR therapy for treating amblyopia in children, showing significant vision improvement and high patient adherence. The study involved 179 patients across 10 clinical sites who utilized proprietary software paired with content partners like Nickelodeon and PBS Kids to improve visual acuity over 12 weeks. These results validate the therapy's clinical benefit as both a first- and second-line treatment, offering a compliant alternative to traditional eye-patching methods.Optometry TimesFDA clears expansion of Luminopia amblyopia treatment to include 8 to 12 year old patientsThe US Food and Drug Administration has cleared Luminopia's amblyopia treatment for patients aged 8 to 12, expanding its approved label from the previous 4 to 7 age range. This regulatory approval is based on real-world evidence from the PUPiL registry and marks the first clearance for this demographic in over two decades, potentially benefiting approximately 400,000 children in the United States.Optometry TimesAnthem Blue Cross Blue Shield approves coverage for amblyopia treatment from LuminopiaAnthem Blue Cross Blue Shield has approved insurance coverage for Luminopia’s VR-based amblyopia treatment, expanding access to the therapy. This decision follows recent FDA clearance extending the treatment's age range from 4-7 years to 4-12 years. The approval by the second-largest US health plan significantly broadens patient eligibility for this digital therapeutic.Ophthalmology TimesPilot Study Indicates Potential Intermittent Exotropia Improvements With Luminopia SoftwareLuminopia reported positive preliminary results from a pilot study indicating that its digital therapeutic software can improve eye movement control in children with intermittent exotropia. The 10-patient trial demonstrated significant improvements in distance control and stereoacuity after three months of therapy, with benefits sustained during a subsequent washout period. These findings support the potential for Luminopia to expand its FDA-cleared platform beyond amblyopia to treat other neuro-visual disorders.pharmaphorumLuminopia's digital therapy for lazy eye aces clinical trialLuminopia reported that its digital therapy Luminopia One significantly outperformed standard glasses-only treatment in a phase 3 clinical trial for amblyopia, with patients showing greater visual acuity improvement and higher adherence rates. The company has submitted the device to the FDA for review, with a decision expected in the coming months.pharmaphorumLuminopia scores FDA approval for TV-based amblyopia therapyLuminopia has received FDA approval for Luminopia One, a digital therapeutic treatment for amblyopia in children aged 4-7 that utilizes modified video content via virtual reality headsets. The approval follows positive Phase 3 clinical trial results showing significant improvement in visual acuity compared to corrective glasses alone. Luminopia plans to begin rolling out the therapy in the first half of next year.Physician's WeeklyLuminopia vs CureSight Cost-Effectiveness for AmblyopiaA retrospective study compared the cost-utility of Luminopia and CureSight against traditional amblyopia treatments like glasses, patching, and atropine. The analysis found that both digital therapies were cost-effective relative to established thresholds, with CureSight demonstrating lower costs per quality-adjusted life-year than Luminopia. Researchers concluded these technologies offer viable alternatives for patients who cannot tolerate conventional methods.TrendHunter.comVR Pediatric TreatmentsLuminopia has entered a content licensing agreement with Spin Master Corp. to expand its library of children's series for its FDA-cleared VR therapy treating amblyopia. This partnership aims to improve patient adherence by integrating popular entertainment franchises into the digital health treatment protocol.PR NewswireLuminopia Teams Up with Spin Master to Bring Popular Children's Programming to Pediatric Amblyopia TreatmentLuminopia announced a licensing agreement with Spin Master to add PAW Patrol, Unicorn Academy, Vida the Vet, and Bakugan to its FDA-cleared amblyopia therapy. The partnership expands content for pediatric patients, addressing amblyopia, the leading cause of vision loss in children. The therapy uses VR headsets to encourage binocular use without eye-patching.VisionmondayLuminopia Announces First International Licensing Agreement With ROHTO Pharmaceutical to Launch Pediatric Amblyopia Treatment in JapanLuminopia Inc. has entered into its first international licensing agreement with ROHTO Pharmaceutical Co. Ltd. to develop and commercialize a digital therapy for pediatric amblyopia in Japan. The deal grants ROHTO exclusive rights to bring Luminopia's FDA-cleared virtual reality treatment to the Japanese market, leveraging local partnerships with content providers like Pokemon and Crunchyroll.